Eden Biodesign and iQur sign deal to develop a combined vaccine for the treatment of hepatitis A and B
05-Feb-2008 -
Eden Biodesign Ltd and iQur Ltd, a speciality pharma company at the forefront of research to combat liver disease, announced that they have entered into an agreement to develop iQur's 'tandem core' vaccine for hepatitis A and B.
Eden Biodesign will develop a unique bio-manufacturing process to ...
antigenes
clinical trials
infectious diseases
+2